文献速递鼻科

度普利尤单抗减少CRSwNP患者全身激素使用与鼻窦手术率

Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP.
PubMed 文献 · Rhinology · 2021-01-01

本文汇总SINUS-24与SINUS-52两项随机双盲安慰剂对照3期研究,评估度普利尤单抗对伴鼻息肉的慢性鼻窦炎(CRSwNP)成人患者的影响。结果显示,度普利尤单抗减少需鼻窦手术的患者数82.6%、研究期间需全身激素(SCS)的患者数73.9%及SCS疗程数75.3%,并显著改善鼻息肉、鼻塞、Lund-MacKay、SNOT-22及UPSIT评分,且不受既往SCS使用或鼻窦手术影响。

要点

  • 度普利尤单抗减少需鼻窦手术患者数82.6%、需SCS患者数73.9%、SCS疗程数75.3%。
  • 无论既往2年内是否使用SCS或是否接受过鼻窦手术,疗效均显著优于安慰剂。
  • 鼻息肉、鼻塞、Lund-MacKay、SNOT-22及UPSIT评分均显著改善。

核心结论

  • 度普利尤单抗在重度CRSwNP患者中显著改善疾病症状与体征,并减少鼻窦手术和SCS使用需求。

研究设计与样本

  • 汇总SINUS-24(NCT02912468)与SINUS-52(NCT02898454)两项随机双盲安慰剂对照3期研究。
  • SINUS-24:患者1:1随机接受皮下度普利尤单抗300 mg(n=143)或安慰剂(n=133)每2周一次,共24周。
  • SINUS-52:患者1:1:1随机接受52周度普利尤单抗300 mg每2周一次(n=150)、24周每2周一次后28周每4周一次(n=145)或52周安慰剂每2周一次(n=153)。

主要发现

  • 度普利尤单抗减少需鼻窦手术的患者数82.6%、研究期间需SCS的患者数73.9%、SCS疗程数75.3%。
  • 与安慰剂相比,度普利尤单抗在鼻息肉、鼻塞、Lund-MacKay、SNOT-22及UPSIT评分上均显著改善。
  • 上述改善不受既往2年内SCS使用或既往鼻窦手术影响。

临床怎么用

  • 对于重度CRSwNP成人患者,度普利尤单抗可作为一种减少手术和SCS使用的治疗选择。
  • 既往SCS使用或鼻窦手术史不影响度普利尤单抗的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease with a high symptom burden and poor quality of life. Treatment options include recurrent surgeries and/or frequent systemic corticosteroids (SCS). Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2-mediated inflammation. We report results of pooled analyses from 2 randomised, double-blind, placebo-controlled phase 3 studies (SINUS 24 [NCT02912468]; SINUS-52 [NCT02898454]) to evaluate dupilumab effect versus placebo in adults with CRSwNP with/without SCS use and sinonasal surgery. METHODOLOGY: SINUS-24 patients were randomised 1:1 to subcutaneous dupilumab 300 mg (n=143) or placebo (n=133) every 2 weeks (q2w) for 24 weeks. SINUS-52 patients were randomised 1:1:1 to 52 weeks of subcutaneous dupilumab 300 mg q2w (n=150), 24 weeks q2w followed by 28 weeks of dupilumab 300 mg every 4 weeks (n=145) or 52 weeks of placebo q2w (n=153). RESULTS: Dupilumab reduced the number of patients undergoing sinonasal surgery (82.6%), the need for in-study SCS use (73.9%), and SCS courses (75.3%). Significant improvements were observed with dupilumab vs placebo regardless of prior sinonasal surgery or SCS use in nasal polyp, nasal congestion, Lund-MacKay, and Sinonasal Outcome Test (22-items) scores, and the University of Pennsylvania Smell Identification Test. CONCLUSIONS: Dupilumab demonstrated significant improvements in disease signs and symptoms and reduced the need for sino-nasal surgery and SCS use versus placebo in patients with severe CRSwNP, regardless of SCS use in the previous 2 years, or prior sinonasal surgery.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. Desrosiers M, Mannent LP, Amin N, et al. Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP. Rhinology. 2021. PMID: 33847325. doi:10.4193/Rhin20.415

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。